

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 45

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Porter Regional Hospital</p> <p>2. 85 East U.S. Highway 6 Valparaiso, IN 46383</p>	<p>In accordance with letter dated May 16, 2013,</p> <p>3. License number 13-17073-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date November 30, 2013</p> <hr/> <p>5. Docket No. 030-12150 Reference No.</p>
--	--

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. One curie
D. Iridium-192 permitted by 10 CFR 35.400	D. Sealed sources (Best Medical International, Inc., Model 81-01)	D. Two curies
E. Iodine-125 permitted by 10 CFR 35.400	E. Sealed sources (Bard Brachytherapy, Inc., Model STM 1251)	E. Two curies
F. Yttrium-90 as permitted by 10 CFR 35.1000	F. Sealed sources (SIR-Spheres AEA Technology QSA GmbH)	F. Two curies

9. Authorized Use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging and localization study permitted by 10 CFR 35.200.
 - C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
 - D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
 - E. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
 - F. For medical use as permitted by 10 CFR 35.1000, in a Sirtex Medical Limited brachytherapy afterloader delivery system.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-17073-01

Docket or Reference Number
030-12150

Amendment No. 45

CONDITIONS

10. A. Licensed material in Subitems 6.A. through 6.F. may be used at the licensee's facilities located at 85 East U.S. Highway 6, Valparaiso, Indiana.
- B. Licensed material in Subitems 6.A. and 6.B. may be used at the licensee's facilities located at 1505 South Calumet, Chesterton, Indiana.
11. A. The Radiation Safety Officer for this license is James M. Forde, M.D.
- B. The Radiation Safety Officer for brachytherapy only is Apparao Devata, Ph.D.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical uses:

Authorized Users

Material and Use

John A. Forchetti, M.D.	10 CFR 35.100 and 35.200.
Hector J. Marchand, M.D.	10 CFR 35.200.
Anil Kothari, M.D.	10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less).
Koppolu P. Sarma, M.D.	10 CFR 35.400.
Kamala Modur, M.D.	10 CFR 35.400.
James M. Forde, M.D.	10 CFR 35.100, 35.200, and 35.300.
Jeffrey M. Huth, M.D.	10 CFR 35.100 and 35.200.
Maximo V. Bleza, D.O.	10 CFR 35.100, 35.200, and 35.300.
Amjad Alkadri, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.1000 (limited to Yttrium-90 as SIR-Spheres).
Jeffrey Jon Quackenbush, M.D.	10 CFR 35.300 and 35.400.
Esther Lee, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the use of iodine-131).
Sandeep Sehgal, M.D.	10 CFR 35.200.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-17073-01

Docket or Reference Number
030-12150

Amendment No. 45

Authorized Users

Material and Use

Keith Atassi, M.D.

10 CFR 35.200.

Michael Wheat, M.D.

10 CFR 35.200.

Vivek Mishra, M.D.


10 CFR 35.100, 35.200, and 35.300 (limited to the use of iodine-131), and **35.1000 (limited to Yttrium-90 as SIR-Spheres).**

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee may transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Materials."
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated July 22, 2003;
- B. Letters dated March 8, 2002, June 20, 2002, March 9, 2004, March 17, 2005, June 3, 2005 (with attached sketch), October 24, 2008, June 4, 2010, January 18, 2012, September 24, 2012, and December 18, 2012; and
- C. Facsimile letters dated September 22, 2005 (with attached sketches), January 2, 2009, and January 6, 2009.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date AUG 12 2013

By



Toy L. Simmons
Materials Licensing Branch
Region III